Phase 1 trials advance promising new immunotherapies for cancer

March 01, 2019

Phase 1 studies are the springboard for advancing new cancer treatments. Through phase 1 studies, the Earle A. Chiles Research Institute, a division of Providence Cancer Institute in the Robert W. Franz Cancer Center, is often able to offer patients first-in-human clinical trials of immunotherapies and other novel cancer therapies, including these two recently opened studies:

A Study of RP1 Monotherapy and RP1 in Combination With Nivolumab

This phase 1/2 first-in-human study will evaluate RP1 alone and in combination with nivolumab in adults with advanced and/or refractory solid tumors. RP1 is a genetically modified herpes simplex type 1 virus that is designed to directly destroy tumors and to generate an anti-tumor immune response. Nivolumab is a PD1 blockade that helps the immune system kill cancer cells. Providence is one of only two sites in the U.S. currently offering this study.

A Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

This is a phase 1/2 first-in-human study of A166 in patients with HER2-expressing or amplified solid tumors who have exhausted available standard therapies. A166 is an antibody drug conjugate that targets HER2-expressing cancer cells.

For more information or to enroll a patient, please call our Clinical Research office at 503-215-2614.

See more studies

Providence Cancer Institute currently offers more than 100 phase 1, 2 and 3 clinical trials. New studies are added frequently. To see all current studies, please visit our website.

An exceptional team

The phase 1 research program at the Earle A. Chiles Research Institute at Providence Cancer Institute is made up of oncology leaders, phase-1-dedicated nurses, data coordinators and lab assistants. Every person on this exceptional team is passionate about offering breakthrough therapies and the best possible treatment for our patients.